Fritextsökning
Innehållstyper
-
Nanexa develops depot formulation of the diabetes and obesity drug Saxenda
Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...
-
Bud på 725 miljoner för Lundabolag – aktien tokrusar
Den nederländska bioläkemedelskoncernen Pharming vill köpa forskningsbolaget Abliva och erbjuder drygt 725 miljoner kronor i köpeskilling.
-
MedVasc and Scientific Solutions join forces to streamline FDA 510(k) regulatory process
MedVasc, an exciting MedTech startup company, and Scientific Solutions, a renowned consulting firm within Life Science, are pleased to announce a strategic part...
-
TCO easy comparison of electric and pneumatic solutions
Find the right technology for your application and compare CO₂ emission and TCO The shown results are not based on a sizing calculation, parameters like service...
-
Meeting with focus on South Korea and Japan’s life sciences
Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage ...
-
A green nursery for biotech rooted in the Scanian soil
Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders...
-
Behöver du vätskekylning under noll grader?
SMC erbjuder cirkulationskylare för en rad olika appikationer och temperaturer, minusgrader inkluderat. Kontakta oss så hittar vi rätt lösning för dig!
-
The stomach medication that became the biggest blockbuster of the 1990s
The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...
-
Eli Lilly to build a USD 2.5-billion plant in Germany
US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.
-
Suing the company – for NOT developing a new HIV drug
Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...
-
EXCL Gantry Kit Improve Automated Lab Applications
We’re excited to introduce a new product that improves precision and throughput in life science applications. The EXCL multi-axis gantry kit lowers engineering ...
-
Lucy Robertshaw: There is a bio revolution happening right now
Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.
-
Tirzepatide approved for obesity by the FDA – to be branded as Zepbound
Diabetes drug tirzepatide has now also been approved in the US for treating obesity.
-
Konsultbolaget Key2compliance köps upp
Det svenska företaget Key2Compliance, som erbjuder tjänster inom bland annat pharma och medtech, förvärvas av tyska GBA Group.
-
The Swedish Life Science Office: “We lost in both coordination and manpower”
Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Depart...
-
Improve your secondary battery manufacturing
SMC provides a large portfolio of products specially designed for secondary battery industry.
-
Ny säljchef på GBA Key2Compliance
Konsultbolaget Key2compliance har rekryterat Anders Jeppson som ny Director of Sales och nu bytt namn till GBA Key2compliance som en följd av att GBA Group tidi...
-
Förändringar i Addvise ledning – tidigare vd-kandidat åtalad
Life science-koncernen Addvise har utsett Fredrik Celsing till ny styrelseordförande efter Staffan Torstensson, som tar över vd-posten i bolaget.
-
The Swedish innovation model: “There is a paradox”
It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?
-
Automated dispensing of liquids
Have a look at how you can do easier and faster dispensing on the fly adapted to your needs
-
Utveckling av svensk KOL-behandling får stöd av amerikansk accelerator
Nystartade Mucolife Therapeutics, som utvecklar ett läkemedel mot lungsjukdomen KOL, har ingått partnerskap med ett amerikanskt acceleratorprogram.
-
Novo Nordisk to invest billions in Danish manufacturing facilities
Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Ka...
-
Mathias Uhlén’s protein atlas is recognised as a global resource
The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark ...
-
The route to vaccines for everyone: “We did not just sit around and wait”
The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a propos...
BREAKING